Art. -Nr.: HY-N0737A

Harmine

(Synonyms: Telepathine)

29 Cited Publications

Kundenbewertung

Based on 29 publication(s) in Google Scholar

Harmine is a natural dual-specificity tyrosine phosphorylation-regulated kinase (DYRK) inhibitor with anticancer and anti-inflammatory activities. Harmine has a high affinity of 5-HT_2A serotonin receptor, with an K_i of 397 nM.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Reinheit: 99.97%
CAS. Nr.: 442-51-3
Formel: C₁₃H₁₂N₂O
Molecular Weight:212.25

Speicherung:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 1 year , -20°C, 6 months

Harmine Chemical Structure

CAS. Nr.: 442-51-3

Größe

Preis

Verfügbarkeit

Menge

Sample (0.1mg)

In-stock

(In Japan)

Apply Now

Angebot einholen Ask For Quote & Lead Time Consult sales personnel for more information Check price and availability Angebot einholen Ask For Quote & Lead Time Consult sales personnel for more information Check price and availability

Massenanfrage

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- IC₅₀ & Target
- Cellular Effect
- In Vitro
- In Vivo
Chemical Information
Publications (29)
Lösungsmittel & Löslichkeit
- In Vitro
- In Vivo
Protokoll
Reinheit & Dokumentation
Verweise
Help & FAQs
Bioz

Biologische Aktivität

Beschreibung

IC₅₀ & Target^[1]^[2]

5-HT_2A Receptor

397 nM (Ki)

5-HT_2A Receptor

DYRK1A

Alle DYRK Isoform-spezifische Produkte anzeigen :

Alle 5-HT Receptor Isoform-spezifische Produkte anzeigen :

Cellular Effect

Cell Line	Type	Value	Description	References
1A9	ED₅₀	1.6 μg/mL Compound: 3	In vitro cytotoxic activity was determined against ovarian cancer (1A9) cell line In vitro cytotoxic activity was determined against ovarian cancer (1A9) cell line	[PMID: 10612592]
769-P	IC₅₀	48.9 μM Compound: 7	Cytotoxicity against human renal carcinoma 769-P cells assessed as reduction in optical density by MTT assay Cytotoxicity against human renal carcinoma 769-P cells assessed as reduction in optical density by MTT assay	[PMID: 23279863]
A-375	IC₅₀	72.5 μM Compound: 7	Cytotoxicity against human malignant melanoma A375 cells assessed as reduction in optical density by MTT assay Cytotoxicity against human malignant melanoma A375 cells assessed as reduction in optical density by MTT assay	[PMID: 23279863]
A549	ED₅₀	2.4 μg/mL Compound: 3	In vitro cytotoxic activity was determined against lung carcinoma (A549) cell line In vitro cytotoxic activity was determined against lung carcinoma (A549) cell line	[PMID: 10612592]
A549	IC₅₀	>20 μM Compound: Harmine	Antiproliferative activity against human A549 cells Antiproliferative activity against human A549 cells	[PMID: 37875056]
A549	IC₅₀	17.12 μM Compound: Harmine	Antiproliferative activity against human A549 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay Antiproliferative activity against human A549 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay	[PMID: 34425477]
A549	IC₅₀	17.3 μM Compound: Cpd I	Antiproliferative activity against human A549 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay Antiproliferative activity against human A549 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay	[PMID: 38154256]
A549	IC₅₀	42.25 μM Compound: Harmine	Cytotoxicity against human A549 cells assessed as inhibition of cell growth after 48 hrs by MTT assay Cytotoxicity against human A549 cells assessed as inhibition of cell growth after 48 hrs by MTT assay	[PMID: 27397495]
A549	IC₅₀	5.23 μM Compound: HM	Antiproliferative activity against human A549 cells assessed as reduction in cell viability incubated for 72 hrs by CCK-8 assay Antiproliferative activity against human A549 cells assessed as reduction in cell viability incubated for 72 hrs by CCK-8 assay	[PMID: 35341920]
A549	IC₅₀	5.89 μM Compound: Harmine	Antiproliferative activity against human A549 cells assessed as reduction in cell viability after 48 hrs by SRB assay Antiproliferative activity against human A549 cells assessed as reduction in cell viability after 48 hrs by SRB assay	[PMID: 31227365]
A549	IC₅₀	52.56 μM Compound: 6; Harmine	Antiproliferative activity against human A549 cells after 24 hrs by MTT assay Antiproliferative activity against human A549 cells after 24 hrs by MTT assay	10.1039/C5MD00581G
A549	IC₅₀	7.76 μM Compound: Har	Antiproliferative activity against human A549 cells after 48 hrs by MTT assay Antiproliferative activity against human A549 cells after 48 hrs by MTT assay	[PMID: 29129513]
Bel-7402	IC₅₀	54 μM Compound: 1	Cytotoxicity against human Bel7402 cells by MTT assay Cytotoxicity against human Bel7402 cells by MTT assay	[PMID: 23291116]
Bel-7402	IC₅₀	54 μM Compound: Harmine	Cytotoxicity against human Bel7402 cells by MTT assay Cytotoxicity against human Bel7402 cells by MTT assay	[PMID: 18462839]
BGC-823	IC₅₀	15.63 μM Compound: HM	Antiproliferative activity against human BGC-823 cells assessed as reduction in cell viability incubated for 72 hrs by CCK-8 assay Antiproliferative activity against human BGC-823 cells assessed as reduction in cell viability incubated for 72 hrs by CCK-8 assay	[PMID: 35341920]
BGC-823	IC₅₀	63.2 μM Compound: 7	Cytotoxicity against human gastric carcinoma BGC823 cells assessed as reduction in optical density by MTT assay Cytotoxicity against human gastric carcinoma BGC823 cells assessed as reduction in optical density by MTT assay	[PMID: 23279863]
BGC-823	IC₅₀	68 μM Compound: 1	Cytotoxicity against human BGC823 cells by MTT assay Cytotoxicity against human BGC823 cells by MTT assay	[PMID: 23291116]
BGC-823	IC₅₀	68 μM Compound: Harmine	Cytotoxicity against human BGC823 cells by MTT assay Cytotoxicity against human BGC823 cells by MTT assay	[PMID: 18462839]
CAKI-1	ED₅₀	1.9 μg/mL Compound: 3	In vitro cytotoxic activity was determined against renal cancer (CAKI-1) cell line In vitro cytotoxic activity was determined against renal cancer (CAKI-1) cell line	[PMID: 10612592]
COLO 205	IC₅₀	26 μM Compound: Harmine	Antiproliferative activity against human COLO205 cells after 24 hrs by MTT assay Antiproliferative activity against human COLO205 cells after 24 hrs by MTT assay	[PMID: 22365759]
COLO 205	IC₅₀	46 μM Compound: Harmine	Cytotoxicity against human COLO205 cells after 24 hrs by MTT assay Cytotoxicity against human COLO205 cells after 24 hrs by MTT assay	[PMID: 22202437]
COLO 205	IC₅₀	8 μM Compound: Harmine	Antiproliferative activity against human COLO205 cells by MTT assay Antiproliferative activity against human COLO205 cells by MTT assay	[PMID: 22749421]
COLO 205	IC₅₀	8 μM Compound: Harmine	Cytotoxicity against human COLO205 cells assessed as decrease in cell viability after 24 hrs by MTT assay Cytotoxicity against human COLO205 cells assessed as decrease in cell viability after 24 hrs by MTT assay	[PMID: 28216402]
DU-145	IC₅₀	12.02 μM Compound: Har	Antiproliferative activity against human DU145 cells after 48 hrs by MTT assay Antiproliferative activity against human DU145 cells after 48 hrs by MTT assay	[PMID: 29129513]
DU-145	IC₅₀	9.63 μM Compound: Harmine	Antiproliferative activity against human DU145 cells assessed as reduction in cell viability after 48 hrs by SRB assay Antiproliferative activity against human DU145 cells assessed as reduction in cell viability after 48 hrs by SRB assay	[PMID: 31227365]
FM3A	EC₅₀	1.8 x 10^-5M Compound: 1i, harmine	In vitro cytotoxic activity tested in mouse mammary tumor FM3A cells In vitro cytotoxic activity tested in mouse mammary tumor FM3A cells	[PMID: 15026051]
H9	EC₅₀	0.52 μM Compound: 9	Antiviral activity against HIV1 in human H9 cells assessed as inhibition of viral replication Antiviral activity against HIV1 in human H9 cells assessed as inhibition of viral replication	[PMID: 11473435]
H9	IC₅₀	26.4 μM Compound: 9	Cytotoxicity against human H9 cells Cytotoxicity against human H9 cells	[PMID: 11473435]
HCT-116	IC₅₀	>20 μM Compound: Harmine	Antiproliferative activity against human HCT-116 cells Antiproliferative activity against human HCT-116 cells	[PMID: 37875056]
HCT-116	IC₅₀	43.8 μM Compound: Harmine	Antiproliferative activity against human HCT116 cells incubated for 48 hrs by MTT assay Antiproliferative activity against human HCT116 cells incubated for 48 hrs by MTT assay	[PMID: 30851694]
HCT-116	IC₅₀	43.8 μM Compound: Harmine	Antiproliferative activity against human HCT-116 cells assessed as inhibition of cell proliferation incubated for 72 hrs by MTT assay Antiproliferative activity against human HCT-116 cells assessed as inhibition of cell proliferation incubated for 72 hrs by MTT assay	[PMID: 35272009]
HCT-116	IC₅₀	46.7 μM Compound: Harmine	Antiproliferative activity against human HCT116 cells assessed as cell viability after 48 hrs by MTT assay Antiproliferative activity against human HCT116 cells assessed as cell viability after 48 hrs by MTT assay	[PMID: 26555243]
HCT-116	IC₅₀	46.7 μM Compound: Harmine	Antiproliferative activity against human HCT116 cells after 48 hrs by MTT assay Antiproliferative activity against human HCT116 cells after 48 hrs by MTT assay	[PMID: 29288941]
HCT-116	IC₅₀	46.7 μM Compound: Harmine	Antiproliferative activity against human HCT116 cells after 48 hrs by MTT assay Antiproliferative activity against human HCT116 cells after 48 hrs by MTT assay	[PMID: 30108831]
HCT-116	IC₅₀	6.94 μM Compound: HM	Antiproliferative activity against human HCT-116 cells assessed as reduction in cell viability incubated for 72 hrs by CCK-8 assay Antiproliferative activity against human HCT-116 cells assessed as reduction in cell viability incubated for 72 hrs by CCK-8 assay	[PMID: 35341920]
HCT-116	IC₅₀	7.64 μM Compound: HAR	Antiproliferative activity against human HCT-116 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Antiproliferative activity against human HCT-116 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 38677112]
HEK293	IC₅₀	0.4 μM Compound: Hrm	Inhibition of tetracycline-inducible EGFP-DYRK1A (unknown origin) expressed in HEK293 cells coexpressing full length human EGFP-tau protein assessed as reduction in tau-Thr212 phosphorylation incubated overnight by immunofluorescence assay Inhibition of tetracycline-inducible EGFP-DYRK1A (unknown origin) expressed in HEK293 cells coexpressing full length human EGFP-tau protein assessed as reduction in tau-Thr212 phosphorylation incubated overnight by immunofluorescence assay	[PMID: 26896709]
HEK-293T	IC₅₀	20.98 μM Compound: HAR	Antiproliferative activity against human HEK293T cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Antiproliferative activity against human HEK293T cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 38677112]
HEL	ED₅₀	1.9 μg/mL Compound: 3	In vitro cytotoxic activity was determined against embryonic lung fibroblast (HEL) cell line In vitro cytotoxic activity was determined against embryonic lung fibroblast (HEL) cell line	[PMID: 10612592]
HeLa	IC₅₀	>10 μM Compound: Harmine	Inhibition of HDAC in human HeLa cell nuclear extract using Boc-Lys (Ac)-AMC as substrate after 60 mins by fluorometric analysis Inhibition of HDAC in human HeLa cell nuclear extract using Boc-Lys (Ac)-AMC as substrate after 60 mins by fluorometric analysis	[PMID: 26555243]
HeLa	IC₅₀	>10 μM Compound: Harmine	Inhibition of HDAC in human HeLa nuclear extract Inhibition of HDAC in human HeLa nuclear extract	[PMID: 30245394]
HeLa	IC₅₀	16.21 μM Compound: Har	Antiproliferative activity against human HeLa cells after 48 hrs by MTT assay Antiproliferative activity against human HeLa cells after 48 hrs by MTT assay	[PMID: 29129513]
HeLa	IC₅₀	60 μM Compound: 1	Cytotoxicity against human HeLa cells by MTT assay Cytotoxicity against human HeLa cells by MTT assay	[PMID: 23291116]
HeLa	IC₅₀	60 μM Compound: Harmine	Cytotoxicity against human HeLa cells by MTT assay Cytotoxicity against human HeLa cells by MTT assay	[PMID: 18462839]
HeLa	IC₅₀	8 μM Compound: Harmine	Cytotoxicity against human HeLa cells after 5 days by MTT assay Cytotoxicity against human HeLa cells after 5 days by MTT assay	[PMID: 30193214]
HeLa	IC₅₀	85.28 μM Compound: 6; Harmine	Antiproliferative activity against human HeLa cells after 24 hrs by MTT assay Antiproliferative activity against human HeLa cells after 24 hrs by MTT assay	10.1039/C5MD00581G
HeLa	IC₅₀	9.66 μM Compound: Harmine	Antiproliferative activity against human HeLa cells assessed as reduction in cell viability after 48 hrs by SRB assay Antiproliferative activity against human HeLa cells assessed as reduction in cell viability after 48 hrs by SRB assay	[PMID: 31227365]
HepG2	IC₅₀	>20 μM Compound: Harmine	Antiproliferative activity against human HepG2 cells Antiproliferative activity against human HepG2 cells	[PMID: 37875056]
HepG2	IC₅₀	>250 μM Compound: HAR	Cytotoxicity against human HepG2 cells assessed as cell growth inhibition incubated for 1 day by neutral red assay Cytotoxicity against human HepG2 cells assessed as cell growth inhibition incubated for 1 day by neutral red assay	[PMID: 34274829]
HepG2	IC₅₀	>250 μM Compound: HAR	Cytotoxicity against human HepG2 cells assessed as cell growth inhibition incubated for 1 day by neutral red assay Cytotoxicity against human HepG2 cells assessed as cell growth inhibition incubated for 1 day by neutral red assay	[PMID: 35551033]
HepG2	IC₅₀	>250 μM Compound: Harmine	Cytotoxicity against human HepG2 cells measured after 24 hrs by neutral red assay Cytotoxicity against human HepG2 cells measured after 24 hrs by neutral red assay	[PMID: 31812035]
HepG2	IC₅₀	>250 μM Compound: HAR	Cytotoxicity against human HepG2 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Cytotoxicity against human HepG2 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 37696205]
HepG2	IC₅₀	14.93 μM Compound: HAR	Antiproliferative activity against human HepG2 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Antiproliferative activity against human HepG2 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 38677112]
HepG2	IC₅₀	16.8 μM Compound: HM	Antiproliferative activity against human HepG2 cells assessed as reduction in cell viability incubated for 72 hrs by CCK-8 assay Antiproliferative activity against human HepG2 cells assessed as reduction in cell viability incubated for 72 hrs by CCK-8 assay	[PMID: 35341920]
HepG2	IC₅₀	19.23 μM Compound: Cpd I	Antiproliferative activity against human HepG2 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay Antiproliferative activity against human HepG2 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay	[PMID: 38154256]
HepG2	IC₅₀	46 μM Compound: 1	Cytotoxicity against human HepG2 cells by MTT assay Cytotoxicity against human HepG2 cells by MTT assay	[PMID: 23291116]
HepG2	IC₅₀	46 μM Compound: Harmine	Cytotoxicity against human HepG2 cells by MTT assay Cytotoxicity against human HepG2 cells by MTT assay	[PMID: 18462839]
HepG2	IC₅₀	49.96 μM Compound: Harmine	Antiproliferative activity against human HepG2 cells by MTT assay Antiproliferative activity against human HepG2 cells by MTT assay	[PMID: 32787089]
HepG2	IC₅₀	51.2 μM Compound: Harmine	Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay	[PMID: 29288941]
HepG2	IC₅₀	51.2 μM Compound: Harmine	Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay	[PMID: 30108831]
HepG2	IC₅₀	53.6 μM Compound: Harmine	Antiproliferative activity against human HepG2 cells incubated for 48 hrs by MTT assay Antiproliferative activity against human HepG2 cells incubated for 48 hrs by MTT assay	[PMID: 30851694]
HepG2	IC₅₀	53.6 μM Compound: Harmine	Antiproliferative activity against human HepG2 cells after 72 hrs by MTT assay Antiproliferative activity against human HepG2 cells after 72 hrs by MTT assay	[PMID: 31120744]
HGC-27	IC₅₀	3.52 μM Compound: Harmine	Antiproliferative activity against human HGC27 cells assessed as reduction in cell viability after 48 hrs by MTT assay Antiproliferative activity against human HGC27 cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 31546197]
HL-60	IC₅₀	62.45 μM Compound: 6; Harmine	Antiproliferative activity against human HL60 cells after 24 hrs by MTT assay Antiproliferative activity against human HL60 cells after 24 hrs by MTT assay	10.1039/C5MD00581G
HL-60	IC₅₀	7.55 μM Compound: 11	Antiproliferative activity against human HL60 cells by tryphan blue assay Antiproliferative activity against human HL60 cells by tryphan blue assay	[PMID: 28128938]
Hs 683	IC₅₀	37 μM Compound: 1	Growth inhibition of human Hs 683 cells after 3 days by MTT assay Growth inhibition of human Hs 683 cells after 3 days by MTT assay	[PMID: 22770529]
Hs 683	IC₅₀	37 μM Compound: 1, Harmine	Cytostatic activity against human Hs683 cells after 72 hrs by videomicroscopy Cytostatic activity against human Hs683 cells after 72 hrs by videomicroscopy	[PMID: 25747498]
HT-22	IC₅₀	56.5 μM Compound: 14	Cytotoxicity against mouse HT-22 cells assessed as reduction in cell viability incubated for 48 hrs by MTS assay Cytotoxicity against mouse HT-22 cells assessed as reduction in cell viability incubated for 48 hrs by MTS assay	[PMID: 36876904]
HT-29	IC₅₀	>20 μM Compound: Harmine	Antiproliferative activity against human HT-29 cells Antiproliferative activity against human HT-29 cells	[PMID: 37875056]
HT-29	IC₅₀	12.15 μM Compound: Cpd I	Antiproliferative activity against human HT-29 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay Antiproliferative activity against human HT-29 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay	[PMID: 38154256]
HT-29	IC₅₀	3.52 μM Compound: Harmine	Antiproliferative activity against human HT-29 cells assessed as reduction in cell viability after 48 hrs by MTT assay Antiproliferative activity against human HT-29 cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 31546197]
HT-29	IC₅₀	41.8 μM Compound: Harmine	Antiproliferative activity against human HT-29 cells by MTT assay Antiproliferative activity against human HT-29 cells by MTT assay	[PMID: 32787089]
IMR-32	IC₅₀	38 μM Compound: Harmine	Antiproliferative activity against human IMR32 cells after 24 hrs by MTT assay Antiproliferative activity against human IMR32 cells after 24 hrs by MTT assay	[PMID: 22365759]
IMR-32	IC₅₀	68 μM Compound: Harmine	Cytotoxicity against human IMR32 cells after 24 hrs by MTT assay Cytotoxicity against human IMR32 cells after 24 hrs by MTT assay	[PMID: 22202437]
K562	IC₅₀	14 μM Compound: Harmine	Antiproliferative activity against human K562 cells by MTT assay Antiproliferative activity against human K562 cells by MTT assay	[PMID: 22749421]
K562	IC₅₀	14 μM Compound: Harmine	Cytotoxicity against human K562 cells assessed as decrease in cell viability after 24 hrs by MTT assay Cytotoxicity against human K562 cells assessed as decrease in cell viability after 24 hrs by MTT assay	[PMID: 28216402]
K562	IC₅₀	32 μM Compound: Harmine	Antiproliferative activity against human K562 cells after 24 hrs by MTT assay Antiproliferative activity against human K562 cells after 24 hrs by MTT assay	[PMID: 22365759]
K562	IC₅₀	45 μM Compound: Harmine	Cytotoxicity against human K562 cells after 24 hrs by MTT assay Cytotoxicity against human K562 cells after 24 hrs by MTT assay	[PMID: 22202437]
K562	IC₅₀	45 μM Compound: Harmine	Antiproliferative activity against human K562 cells assessed as cell growth inhibition after 24 hrs by MTT assay Antiproliferative activity against human K562 cells assessed as cell growth inhibition after 24 hrs by MTT assay	[PMID: 22516283]
KB	ED₅₀	2.2 μg/mL Compound: 3	In vitro cytotoxic activity was determined against epidermoid carcinoma of the nasopharynx (KB) cell line In vitro cytotoxic activity was determined against epidermoid carcinoma of the nasopharynx (KB) cell line	[PMID: 10612592]
KB	ED₅₀	2.5 μg/mL Compound: 3	In vitro cytotoxic activity was determined against drug resistant tumor cell line KB-VIN (expressing P-glycoprotein) In vitro cytotoxic activity was determined against drug resistant tumor cell line KB-VIN (expressing P-glycoprotein)	[PMID: 10612592]
KB	ED₅₀	3.7 μg/mL Compound: 3	In vitro cytotoxic activity was determined against drug resistant tumor cell line KB-7d (pleotrophic resistance including MRP multidrug resistant protein) In vitro cytotoxic activity was determined against drug resistant tumor cell line KB-7d (pleotrophic resistance including MRP multidrug resistant protein)	[PMID: 10612592]
KB	ED₅₀	4.3 μg/mL Compound: 3	In vitro cytotoxic activity was determined against drug resistant tumor cell line KB-CPT (pleotrophic mechanism including level of topoisomerase I) In vitro cytotoxic activity was determined against drug resistant tumor cell line KB-CPT (pleotrophic mechanism including level of topoisomerase I)	[PMID: 10612592]
KB	IC₅₀	57.8 μM Compound: 7	Cytotoxicity against human epidermoid carcinoma of the nasopharynx KB cells assessed as reduction in optical density by MTT assay Cytotoxicity against human epidermoid carcinoma of the nasopharynx KB cells assessed as reduction in optical density by MTT assay	[PMID: 23279863]
L02	IC₅₀	25.09 μM Compound: HM	Cytotoxicity against human L02 cells assessed as reduction in cell viability incubated for 72 hrs by CCK-8 assay Cytotoxicity against human L02 cells assessed as reduction in cell viability incubated for 72 hrs by CCK-8 assay	[PMID: 35341920]
L02	IC₅₀	9.49 μM Compound: Cpd I	Cytotoxicity against human L02 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay Cytotoxicity against human L02 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay	[PMID: 38154256]
LoVo	IC₅₀	53.2 μM Compound: Harmine	Antiproliferative activity against human LoVo cells assessed as cell viability after 48 hrs by MTT assay Antiproliferative activity against human LoVo cells assessed as cell viability after 48 hrs by MTT assay	[PMID: 26555243]
LoVo	IC₅₀	53.2 μM Compound: Harmine	Antiproliferative activity against human LoVo cells after 48 hrs by MTT assay Antiproliferative activity against human LoVo cells after 48 hrs by MTT assay	[PMID: 30108831]
MCF7	ED₅₀	10.5 μg/mL Compound: 3	In vitro cytotoxic activity against MCF-7 (human breast cancer) cell line. In vitro cytotoxic activity against MCF-7 (human breast cancer) cell line.	[PMID: 10612592]
MCF7	IC₅₀	10.78 μM Compound: Har	Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay	[PMID: 29129513]
MCF7	IC₅₀	13.37 μM Compound: Cpd I	Antiproliferative activity against human MCF7 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay Antiproliferative activity against human MCF7 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay	[PMID: 38154256]
MCF7	IC₅₀	13.5 μM Compound: HAR	Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 38677112]
MCF7	IC₅₀	15.27 μM Compound: HM	Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability incubated for 72 hrs by CCK-8 assay Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability incubated for 72 hrs by CCK-8 assay	[PMID: 35341920]
MCF7	IC₅₀	16.94 μM Compound: Harmine	Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability incubated for 72 hrs by CCK-8 assay Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability incubated for 72 hrs by CCK-8 assay	[PMID: 33744443]
MCF7	IC₅₀	3.52 μM Compound: Harmine	Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability after 72 hrs by MTT assay Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 31546197]
MCF7	IC₅₀	68.33 μM Compound: Harmine	Cytotoxicity against human MCF7 cells assessed as inhibition of cell growth after 48 hrs by MTT assay Cytotoxicity against human MCF7 cells assessed as inhibition of cell growth after 48 hrs by MTT assay	[PMID: 27397495]
MCF7	IC₅₀	70.7 μM Compound: 6; Harmine	Antiproliferative activity against human MCF7 cells after 24 hrs by MTT assay Antiproliferative activity against human MCF7 cells after 24 hrs by MTT assay	10.1039/C5MD00581G
MCF7	IC₅₀	72 μM Compound: Harmine	Cytotoxicity against human MCF7 cells by MTT assay Cytotoxicity against human MCF7 cells by MTT assay	[PMID: 18462839]
MDA-MB-231	IC₅₀	13.21 μM Compound: Cpd I	Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay	[PMID: 38154256]
MDA-MB-231	IC₅₀	21.91 μM Compound: Harmine	Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell viability incubated for 72 hrs by CCK-8 assay Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell viability incubated for 72 hrs by CCK-8 assay	[PMID: 33744443]
MDA-MB-231	IC₅₀	32 μM Compound: Harmine	Antiproliferative activity against human MDA-MB-231 cells by MTT assay Antiproliferative activity against human MDA-MB-231 cells by MTT assay	[PMID: 22749421]
MDA-MB-231	IC₅₀	32 μM Compound: Harmine	Cytotoxicity against human MDA-MB-231 cells assessed as decrease in cell viability after 24 hrs by MTT assay Cytotoxicity against human MDA-MB-231 cells assessed as decrease in cell viability after 24 hrs by MTT assay	[PMID: 28216402]
MDA-MB-231	IC₅₀	54 μM Compound: Harmine	Cytotoxicity against human MDA-MB-231 cells after 24 hrs by MTT assay Cytotoxicity against human MDA-MB-231 cells after 24 hrs by MTT assay	[PMID: 22202437]
MDA-MB-231	IC₅₀	54 μM Compound: Harmine	Antiproliferative activity against human MDA-MB-231 cells assessed as cell growth inhibition after 24 hrs by MTT assay Antiproliferative activity against human MDA-MB-231 cells assessed as cell growth inhibition after 24 hrs by MTT assay	[PMID: 22516283]
MDA-MB-435	IC₅₀	>100 μM Compound: Harmine	Cytotoxicity against human MDA-MB-435 cells assessed as reduction in cell viability incubated for 1 day by MTT assay Cytotoxicity against human MDA-MB-435 cells assessed as reduction in cell viability incubated for 1 day by MTT assay	[PMID: 33813152]
MDA-MB-435	IC₅₀	17.1 μM Compound: Harmine	Antiproliferative activity against human MDA-MB-435 cells assessed as inhibition of cell growth incubated for 5 days by MTT assay Antiproliferative activity against human MDA-MB-435 cells assessed as inhibition of cell growth incubated for 5 days by MTT assay	[PMID: 33813152]
MDCK-II	GI₅₀	2.3 μM Compound: Harmine	Cytotoxicity against wild-type MDCK2 cells assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against wild-type MDCK2 cells assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 27280693]
MDCK-II	GI₅₀	2.42 μM Compound: Harmine	Cytotoxicity against MDCK2 cells expressing human ABCG2 assessed as reduction in cell viability after 72 hrs by MTT assay Cytotoxicity against MDCK2 cells expressing human ABCG2 assessed as reduction in cell viability after 72 hrs by MTT assay	[PMID: 27280693]
NCI-H2228	IC₅₀	31.06 μM Compound: Harmine	Antiproliferative activity against human EML4-ALK positive H2228 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay Antiproliferative activity against human EML4-ALK positive H2228 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay	[PMID: 34425477]
OE33	IC₅₀	18 μM Compound: 1	Growth inhibition of human OE33 cells after 3 days by MTT assay Growth inhibition of human OE33 cells after 3 days by MTT assay	[PMID: 22770529]
Pancreatic beta cell	EC₅₀	7.48 μM Compound: Telepathine	Induction of cell proliferation in rat beta cells Induction of cell proliferation in rat beta cells	[PMID: 32077280]
PC-3	IC₅₀	15.57 μM Compound: Cpd I	Antiproliferative activity against human PC-3 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay Antiproliferative activity against human PC-3 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay	[PMID: 38154256]
PC-3	IC₅₀	3.52 μM Compound: Harmine	Antiproliferative activity against human PC3 cells assessed as reduction in cell viability after 48 hrs by MTT assay Antiproliferative activity against human PC3 cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 31546197]
Platelet	IC₅₀	>130 μM Compound: Harmine	Antiplatelet aggregation activity against collagen-induced platelet Antiplatelet aggregation activity against collagen-induced platelet	[PMID: 20329729]
Platelet	IC₅₀	130 μM Compound: Harmine	Antiplatelet activity in rabbit platelets assessed as inhibition of collagen-induced platelet aggregation Antiplatelet activity in rabbit platelets assessed as inhibition of collagen-induced platelet aggregation	[PMID: 21983333]
SGC-7901	IC₅₀	40.82 μM Compound: Harmine	Cytotoxicity against human SGC7901 cells assessed as inhibition of cell growth after 48 hrs by MTT assay Cytotoxicity against human SGC7901 cells assessed as inhibition of cell growth after 48 hrs by MTT assay	[PMID: 27397495]
SGC-7901	IC₅₀	70.36 μM Compound: 6; Harmine	Antiproliferative activity against human SGC7901 cells after 24 hrs by MTT assay Antiproliferative activity against human SGC7901 cells after 24 hrs by MTT assay	10.1039/C5MD00581G
SK-MEL-2	ED₅₀	18.5 μg/mL Compound: 3	In vitro cytotoxic activity was determined against melanoma cancer (SK-MEL-2) cell line In vitro cytotoxic activity was determined against melanoma cancer (SK-MEL-2) cell line	[PMID: 10612592]
SK-OV-3	IC₅₀	74.6 μM Compound: 7	Cytotoxicity against human ovary adenocarcinoma SKOV3 cells assessed as reduction in optical density by MTT assay Cytotoxicity against human ovary adenocarcinoma SKOV3 cells assessed as reduction in optical density by MTT assay	[PMID: 23279863]
SMMC-7721	IC₅₀	47.6 μM Compound: Harmine	Antiproliferative activity against human SMMC7721 cells incubated for 48 hrs by MTT assay Antiproliferative activity against human SMMC7721 cells incubated for 48 hrs by MTT assay	[PMID: 30851694]
SMMC-7721	IC₅₀	47.6 μM Compound: Harmine	Antiproliferative activity against human SMMC7721 cells after 72 hrs by MTT assay Antiproliferative activity against human SMMC7721 cells after 72 hrs by MTT assay	[PMID: 31120744]
SMMC-7721	IC₅₀	55.3 μM Compound: Harmine	Antiproliferative activity against human SMMC7721 cells after 48 hrs by MTT assay Antiproliferative activity against human SMMC7721 cells after 48 hrs by MTT assay	[PMID: 29288941]
SMMC-7721	IC₅₀	55.3 μM Compound: Harmine	Antiproliferative activity against human SMMC7721 cells after 48 hrs by MTT assay Antiproliferative activity against human SMMC7721 cells after 48 hrs by MTT assay	[PMID: 30108831]
SMMC-7721	IC₅₀	59.44 μM Compound: Harmine	Cytotoxicity against human SMMC7721 cells assessed as inhibition of cell growth after 48 hrs by MTT assay Cytotoxicity against human SMMC7721 cells assessed as inhibition of cell growth after 48 hrs by MTT assay	[PMID: 27397495]
SW-620	IC₅₀	42.8 μM Compound: Harmine	Antiproliferative activity against human SW620 cells assessed as cell viability after 48 hrs by MTT assay Antiproliferative activity against human SW620 cells assessed as cell viability after 48 hrs by MTT assay	[PMID: 26555243]
SW-620	IC₅₀	7.32 μM Compound: HAR	Antiproliferative activity against human SW620 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Antiproliferative activity against human SW620 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 38677112]
T98G	IC₅₀	24 μM Compound: 1	Growth inhibition of human T98G cells after 3 days by MTT assay Growth inhibition of human T98G cells after 3 days by MTT assay	[PMID: 22770529]
U-373MG ATCC	IC₅₀	32 μM Compound: 1	Growth inhibition of human U373 cells after 3 days by MTT assay Growth inhibition of human U373 cells after 3 days by MTT assay	[PMID: 22770529]
U-87MG ATCC	ED₅₀	14.5 μg/mL Compound: 3	In vitro cytotoxic activity against U-87-MG (glioblastoma) cell line. In vitro cytotoxic activity against U-87-MG (glioblastoma) cell line.	[PMID: 10612592]
U-87MG ATCC	IC₅₀	7.2 μM Compound: Hrm	Growth inhibition of human U87MG cells after 4 days by MTT assay Growth inhibition of human U87MG cells after 4 days by MTT assay	[PMID: 26896709]

In Vitro

Harmine inhibits tau phosphorylation by DYRK1A by selected DANDYs, with an IC₅₀ of 190 nM^[2].Harmine negatively regulates homologous recombination (HR) by interfering Rad51 recruitment, resulting in severe cytotoxicity in hepatoma cells. Furthermore, NHEJ inhibitor Nu7441 markedly sensitizes Hep3B cells to the anti-proliferative effects of Harmine^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

It is shown that brain water content is significantly increased in the TBI group. Treatment with Harmine significantly reduces the tissue water content at 1, 3 and 5 days, compared with the TBI group. Harmine treatment significantly reduces the escape latency at 3 and 5 days, compared with the TBI group. Post-TBI administration of Harmine significantly improves the motor function recovery of the rats at 1, 3 and 5 days following TBI, compared with the TBI group without Harmine treatment. The neuronal survival rate in the Harmine-treated group is significantly increased, compared with the TBI group. Administration of Harmine results in marked elevation in the expression of GLT-1, compared with the TBI group. The administration of Harmine significantly reduces the expression of caspase 3, compared with the TBI group^[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Chemical Information

CAS. Nr. 442-51-3
Appearance Solid
Molecular Weight 212.25
Formel C₁₃H₁₂N₂O
Color White to yellow
SMILES

CC1=NC=CC2=C1NC3=C2C=CC(OC)=C3
Synonyms

Telepathine
Structure Classification
- Alkaloids
- Indole Alkaloids
Initial Source
Versand

Room temperature in continental US; may vary elsewhere.

Speicherung

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	1 year
	-20°C	6 months

Publications (29)

All WBCell Migration/Invasion AssayIn Vivo Efficacy StudyIF

Sort by:

Journal Impact Factor

Cell Stem Cell

A small-molecule cocktail promotes mammalian cardiomyocyte proliferation and heart regeneration. [Abstract]

2022 Apr 7;29(4):545-558.e13. PMID: 35395187
J Clin Invest

TWIST1+FAP+ fibroblasts in the pathogenesis of intestinal fibrosis in Crohn's disease. [Abstract]

2024 Jul 18:e179472. PMID: 39024569

Harmine purchased from MedChemExpress. Usage Cited in: J Clin Invest. 2024 Jul 18:e179472. [Abstract]

Western blotting images showing the expression of ECM-related genes in primary human intestinal fibroblasts with or without TGF-β (5 ng/mL, 48 hours) and Harmine administration (5 μM or 10 μM, 48 hours).

Harmine purchased from MedChemExpress. Usage Cited in: J Clin Invest. 2024 Jul 18:e179472. [Abstract]

Masson’s trichrome staining showing collagen deposition in mouse colons across the 4 indicated groups. Twist1^fl/fl mice and Col1a2-Cre^ERT2Twist1^fl/fl cohoused littermates (8 weeks old) were injected intraperitoneally with tamoxifen daily for 4 days (100 mg per kg body weight each time). The mice were subjected to 3 cycles of DSS administration (7 days of DSS administration followed by 14 days of regular drinking water). Harmine (10 mg/kg) was injected intraperitoneally twice a week during each DSS cycle (regularly on Tuesday and Friday weekly).

Harmine purchased from MedChemExpress. Usage Cited in: J Clin Invest. 2024 Jul 18:e179472. [Abstract]

Representative IF staining of mouse colons across the 4 indicated groups (original magnification, ×20). DAPI (blue), COL1A1 (red), and vimentin (green) in merged channels are shown. Twist1^fl/fl mice and Col1a2-Cre^ERT2Twist1^fl/fl cohoused littermates (8 weeks old) were injected intraperitoneally with tamoxifen daily for 4 days (100 mg per kg body weight each time). The mice were subjected to 3 cycles of DSS administration (7 days of DSS administration followed by 14 days of regular drinking water). Harmine (10 mg/kg) was injected intraperitoneally twice a week during each DSS cycle (regularly on Tuesday and Friday weekly).
Sci Adv

Haploid-genetic screening of trophectoderm specification identifies Dyrk1a as a repressor of totipotent-like status. [Abstract]

2023 Dec 22;9(51):eadi5683. PMID: 38117886
J Biomed Sci

DYRK1A reinforces epithelial-mesenchymal transition and metastasis of hepatocellular carcinoma via cooperatively activating STAT3 and SMAD. [Abstract]

2022 Jun 2;29(1):34. PMID: 35655269

Harmine purchased from MedChemExpress. Usage Cited in: J Biomed Sci. 2022 Jun 2;29(1):34. [Abstract]

HepG2 cells were incubated with Harmine (0, 2, 4, 8 μM) and were then cultured in the upper compartment of Transwell chambers for 24 h. Then, the cells were stained with crystal violet solution.

Harmine purchased from MedChemExpress. Usage Cited in: J Biomed Sci. 2022 Jun 2;29(1):34. [Abstract]

Following treatment with Harmine (0, 5, 10, 20 μM) for 24 h at the indicated concentrations, total protein was extracted from HEPG2 and Hep3B cells and analysed by western blotting.

Harmine purchased from MedChemExpress. Usage Cited in: J Biomed Sci. 2022 Jun 2;29(1):34. [Abstract]

HCC cells were serum-starved overnight, a scratch was created, and the cells were then incubated with 10 μM harmine and/or 10 ng/mL TGF-β for 6 h. Images were acquired under a microscope.

Harmine purchased from MedChemExpress. Usage Cited in: J Biomed Sci. 2022 Jun 2;29(1):34. [Abstract]

Cells were serum-starved overnight and were then treated with Harmine (10 μM) or 10 ng/mL TGF-β for 6 h. Western blot analysis was then performed.
Cancer Biol Med

DYRK1A suppression restrains Mcl-1 expression and sensitizes NSCLC cells to Bcl-2 inhibitors. [Abstract]

2020 May 15;17(2):387-400. PMID: 32587776
Phytomedicine

Genkwanin reduces airway epithelial cell ferroptosis and alleviates asthma symptoms in mice. [Abstract]

2025 Sep 24:148:157306. PMID: 41046685
Phytomedicine

Fangchinoline suppresses nasopharyngeal carcinoma progression by inhibiting SQLE to regulate the PI3K/AKT pathway dysregulation. [Abstract]

2025 May:140:156484. PMID: 40090046
Biochem Pharmacol

Harmine inhibits ovarian cancer migration and invasion and epithelial-mesenchymal transition (EMT) by inhibiting HDAC7 to restore RECK expression. [Abstract]

2025 Oct 7;242(Pt 4):117391. PMID: 41061932
J Ethnopharmacol

Qianyang Yuyin granules alleviate hypertension-induced vascular remodeling by inhibiting the phenotypic switch of vascular smooth muscle cells. [Abstract]

2025 Jan 30;337(Pt 3):118896. PMID: 39393558
Int J Oncol

DYRK1A suppression attenuates HIF‑1α accumulation and enhances the anti‑liver cancer effects of regorafenib and sorafenib under hypoxic conditions. [Abstract]

2022 Apr;60(4):45. PMID: 35244188
Int Immunopharmacol

Harmine attenuates renal fibrosis via Twist1 suppression: A novel anti-fibrotic strategy for chronic kidney disease with efficacy/safety profiling. [Abstract]

2026 Jan 1;168(Pt 2):115902. PMID: 41273846
Eur J Pharmacol

Harmine-induced disruption of the blood-brain barrier via excessive mitophagy in zebrafish. [Abstract]

2024 Dec 30:177223. PMID: 39742937
Eur J Pharmacol

MFN2-dependent mitochondrial dysfunction contributes to Relm-β-induced pulmonary arterial hypertension via USP18/Twist1/miR-214 pathway. [Abstract]

2024 Jul 31:980:176828. PMID: 39094924
Int Immunopharmacol

Harmine exerts anxiolytic effects by regulating neuroinflammation and neuronal plasticity in the basolateral amygdala. [Abstract]

2023 Jun:119:110208. PMID: 37150016
Front Cell Dev Biol

Harmine Alleviated Sepsis-Induced Cardiac Dysfunction by Modulating Macrophage Polarization via the STAT/MAPK/NF-κB Pathway. [Abstract]

2022 Jan 17;9:792257. PMID: 35111758
J Cell Mol Med

DYRK1A inhibition suppresses STAT3/EGFR/Met signalling and sensitizes EGFR wild-type NSCLC cells to AZD9291. [Abstract]

2019 Nov;23(11):7427-7437. PMID: 31454149
J Biol Chem

Harmine promotes axon regeneration through enhancing glucose metabolism. [Abstract]

2025 Feb 2:108254. PMID: 39904483
Sci Rep

The roles of autophagy, ferroptosis and pyroptosis in the anti-ovarian cancer mechanism of harmine and their crosstalk. [Abstract]

2024 Mar 18;14(1):6504. PMID: 38499622
Biomedicines

A Novel Druggable Dual-Specificity tYrosine-Regulated Kinase3/Calmodulin Kinase-like Vesicle-Associated Signaling Module with Therapeutic Implications in Neuroblastoma. [Abstract]

2024 Jan 16;12(1):197. PMID: 38255303
Prog Neuropsychopharmacol Biol Psychiatry

Harmine produces antidepressant-like effects via restoration of astrocytic functions. [Abstract]

2017 Jun 15;79(Pt B):258-267. PMID: 28625859

Harmine purchased from MedChemExpress. Usage Cited in: Prog Neuropsychopharmacol Biol Psychiatry. 2017 Jun 15;79(Pt B):258-267. [Abstract]

Representative images showing the restoration effect of Harmine on CUS-induced decrease in hippocampal DCX protein expressions. The Fluoxetine administration (20 mg/kg) is used as a positive control, and all data are shown as mean±SEM.
Sci Rep

Identification of a DYRK1A Inhibitor that Induces Degradation of the Target Kinase using Co-chaperone CDC37 fused with Luciferase nanoKAZ. [Abstract]

2015 Aug 3;5:12728. PMID: 26234946
BMC Infect Dis

Harmine acts as a quorum sensing inhibitor decreasing the virulence and antibiotic resistance of Pseudomonas aeruginosa. [Abstract]

2024 Jul 31;24(1):760. PMID: 39085766
Onco Targets Ther

Harmine suppresses the proliferation of pancreatic cancer cells and sensitizes pancreatic cancer to gemcitabine treatment. [Abstract]

2019 Jun 12:12:4585-4593. PMID: 31354292
J Integr Neurosci

Harmine-mediated Reduction of Bone Cancer Pain in Rats Correlates With Suppressed DYRK1A/NF-κB Signaling Axis. [Abstract]

2025 Jun 23;24(6):38100. PMID: 40613372
Exp Ther Med

Harmine reinforces the effects of regorafenib on suppressing cell proliferation and inducing apoptosis in liver cancer cells. [Abstract]

2022 Mar;23(3):209. PMID: 35126712
Res Sq

2025 Jul 08.
bioRxiv

2023 Dec 1.
SSRN

2023 Mar 8.
Research Square Preprint

2021 Aug.

Lösungsmittel & Löslichkeit

In Vitro:

DMSO : ≥ 30 mg/mL (141.34 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

* "≥" means soluble, but saturation unknown.

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

4.7114 mL

23.5571 mL

47.1143 mL

5 mM

0.9423 mL

4.7114 mL

9.4229 mL

10 mM

0.4711 mL

2.3557 mL

4.7114 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.5 mg/mL (11.78 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.5 mg/mL (11.78 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Protokoll

Animal Administration^[4]

Rats^[4]
A total of 150 male Sprague-Dawley rats (age, 10-12 weeks; weighing, 280-320 g; are used in the present study. The rats are randomly divided into three groups: Sham-operated group (sham; n=15); the TBI group (TBI; n=35) and the TBI + Harmine-treated group (Harmine; n=35). Harmine is administered immediately following TBI (i.p, 30 mg/kg per day) for up to 5 days. The sham and TBI groups receive equal volumes of 0.9% saline solution (i.p.). The rats are grouped as follows for examination of behavioral recovery: Sham, n=3; TBI, n=7; and Harmine, n=7. Following TBI, the NSS is evaluated at 1, 3 and 5 days. Each rat is assessed by an observer who is blinded to the animal treatment^[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (281 KB)
SDS (396 KB)
- English - EN (396 KB)
- Français - FR (396 KB)
- Deutsch - DE (396 KB)
- Norwegian - NO (396 KB)
- Español - ES (396 KB)
- Swedish - SV (396 KB)
- Italian - IT (396 KB)
- Portuguese - PT (396 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. Glennon RA, et al. Binding of beta-carbolines and related agents at serotonin (5-HT(2) and 5-HT(1A)), dopamine (D(2)) and benzodiazepine receptors. Drug Alcohol Depend. 2000 Aug 1;60(2):121-32. [Content Brief]

[2]. Neumann F, et al. DYRK1A inhibition and cognitive rescue in a Down syndrome mouse model are induced by new fluoro-DANDY derivatives. Sci Rep. 2018 Feb 12;8(1):2859. [Content Brief]

[3]. Zhang L, et al. Harmine suppresses homologous recombination repair and inhibits proliferation of hepatoma cells. Cancer Biol Ther. 2015;16(11):1585-92. [Content Brief]

[4]. Zhong Z, et al. Treatment with harmine ameliorates functional impairment and neuronal death following traumatic brain injury. Mol Med Rep. 2015 Dec;12(6):7985-91. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	4.7114 mL	23.5571 mL	47.1143 mL	117.7856 mL
	5 mM	0.9423 mL	4.7114 mL	9.4229 mL	23.5571 mL
	10 mM	0.4711 mL	2.3557 mL	4.7114 mL	11.7786 mL
	15 mM	0.3141 mL	1.5705 mL	3.1410 mL	7.8524 mL
	20 mM	0.2356 mL	1.1779 mL	2.3557 mL	5.8893 mL
	25 mM	0.1885 mL	0.9423 mL	1.8846 mL	4.7114 mL
	30 mM	0.1570 mL	0.7852 mL	1.5705 mL	3.9262 mL
	40 mM	0.1178 mL	0.5889 mL	1.1779 mL	2.9446 mL
	50 mM	0.0942 mL	0.4711 mL	0.9423 mL	2.3557 mL
	60 mM	0.0785 mL	0.3926 mL	0.7852 mL	1.9631 mL
	80 mM	0.0589 mL	0.2945 mL	0.5889 mL	1.4723 mL
	100 mM	0.0471 mL	0.2356 mL	0.4711 mL	1.1779 mL

Keywords

Harmine

29 Cited Publications

100 mg Angebot einholen

Subscribe to the

MedChemExpress

Newsletter

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge:

Harmine

GPCR/G Protein Compound Library

Immunology/Inflammation Compound Library

Kinase Inhibitor Library

Neuronal Signaling Compound Library

Protein Tyrosine Kinase Compound Library

Natural Product Library

Anti-Cancer Compound Library

CNS-Penetrant Compound Library

Medicine Food Homology Compound Library

Neurotransmitter Receptor Compound Library

Traditional Chinese Medicine Active Compound Library

FDA Approved & Pharmacopeial Drug Library

Anti-Alzheimer's Disease Compound Library

Alkaloids Library

Anti-Parkinson's Disease Compound Library

Neurodegenerative Disease-related Compound Library

Anti-Obesity Compound Library

Anti-Cancer Natural Product Library

Anti-inflammatory Traditional Chinese Medicine Active Compound Library

Plant-Sourced Natural Product Library

5-HT Receptor Compound Library

Human Metabolite Library

Coagulation and Anti-coagulation Compound Library

Heterocyclic Compound Library

Membrane Protein-targeted Compound Library

Membrane Receptor-targeted Compound Library

Highly Selective Inhibitors Library

Serine/Threonine Kinase Inhibitor Library

Multi-Target Compound Library

Bioactive Compound Library Max

Kinase Inhibitor Library Mini

MCE Bioactive Compound Library

Natural Product Library Plus

Natural Product and Natural Product-Like Compound Library

Bioactive Compound Library

Miao Ethnicity Medicine Compound Library

Tibetan Medicine Compound Library

PBCRBS Traditional Chinese Medicine Compound Library

Protein Kinase Compound Library

RO5 Drug-like Natural Product Library

High-Throughput Bioactive Compound Library

High-Throughput Natural Product Library

Ancient Chinese Classical Formulas Traditional Chinese Medicine Active Compound Library

Mass Spectrometry Human Metabolite Library

Diarrhea-Related Traditional Chinese Medicine Active Compound Library

Posttranslational Modification Library

Mongolian Medicine Compound Library

Chinese Baijiu Compound Library

Tonifying Traditional Chinese Medicine Monomer Compound Library

RNA Binding Bioactive Compound Library

Lactylation Compound Library

Mass Spectrometry Natural Product Library

Publications Citing Use of MedChemExpress (MCE) Harmine

Alle DYRK Isoform-spezifische Produkte anzeigen

Alle 5-HT Receptor Isoform-spezifische Produkte anzeigen

Biologische Aktivität

Chemical Information

Publications (29)

Lösungsmittel & Löslichkeit

Protokoll

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

Harmine Related Classifications

Art. -Nr.: HY-N0737A